Adverse reactions in two patients who received HMG CoA reductase inhibitor therapy were reinvestigated because of their rarity. A case of permanent forearm myalgia was thought to be caused by atorvastatin. Closer evaluation and work-up revealed underlying lateral epicondylitis, and atorvastatin was not considered the cause of the disability. In another patient, rhabdomyolysis was suspected to be secondary to simvastatin. However, after an extensive review, the reaction was believed to be compartment syndrome of the anterior tibial area. An adverse drug reaction report requires careful and judicious assessment to assign the correct probability for the event.

Successful treatment of eating disorders often includes drug therapy along with psychotherapy and nutritional counseling. Selective serotonin reuptake inhibitors are attractive agents for use in eating disorders due to their favorable side effect profiles. Currently, fluoxetine is the only FDA approved agent for treatment of bulimia nervosa; however, fluvoxamine has also been studied for use in this disorder. This review examines the evidence for the use of selective serotonin reuptake inhibitors in bulimia, and summarizes the pharmacokinetics, side effects, and drug interactions of selective serotonin reuptake inhibitors available in the United States.